The medical organisation Médecins Sans Frontières (MSF) welcomes the introduction of a new user-friendly and cheaper 2-in-1 tablet of artesunate-amodiaquine against malaria. The treatment, also called ASAQ, is the result of research by the non-profit Drugs for Neglected Diseases initiative (DNDi) in cooperation with Sanofi-Aventis. It demonstrates how research and development can take place without patenting for availability in the public domain.
More...
Sunday, March 04, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment